✦ LIBER ✦

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

✍ Scribed by K. G. C. Smith; R. B. Jones; S. M. Burns; D. R. W. Jayne

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 519 KB
Volume: 54
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.22046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term treatment of systemic lupus er

Long-term treatment of systemic lupus erythematosus with cyclosporin A

✍ Domenico Caccavo; Bruno Laganà; Anna P. Mitterhofer; Giovanni M. Ferri; Antonell 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 864 KB

Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE). Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective,

Prolonged remission without treatment af

Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus

✍ N. M. Wulffraat; E. A. M. Sanders; S. S. M. Kamphuis; G. T. Rijkers; W. Kuis; M. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 1 views

Differences in long-term disease activit

Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus

✍ Hersh, Aimee O. ;von Scheven, Emily ;Yazdany, Jinoos ;Panopalis, Pantelis ;Trupi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 3 views

B cell depletion as a novel treatment fo

B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab

✍ R. John Looney; Jennifer H. Anolik; Debbie Campbell; Raymond E. Felgar; Faith Yo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

## Abstract ## Objective Safer and more effective therapies are needed for the treatment of systemic lupus erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for

Effect of long-term belimumab treatment

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

✍ Annett M. Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB